Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. TMO
TMO logo

TMO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
504.020
Open
496.220
VWAP
499.34
Vol
1.13M
Mkt Cap
186.47B
Low
492.150
Amount
564.85M
EV/EBITDA(TTM)
19.84
Total Shares
371.48M
EV
215.88B
EV/OCF(TTM)
27.61
P/S(TTM)
4.26
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.
Show More

Events Timeline

(ET)
2026-03-02
09:20:00
AIM ImmunoTech Partners with Thermo Fisher to Design Phase 3 Pancreatic Cancer Trial
select
2026-02-25 (ET)
2026-02-25
17:10:00
Dividend Payable on April 15, 2026
select
2026-01-30 (ET)
2026-01-30
10:50:00
Nvidia, Amazon, and Microsoft Plan to Invest Up to $60B in OpenAI
select
2026-01-29 (ET)
2026-01-29
09:00:00
FY26 Revenue Expected at $46.3B-$47.2B
select
2026-01-29
09:00:00
U.S. Stock Futures Rise as Tech Earnings Impact Sentiment
select
2026-01-29
06:10:00
Thermo Fisher Reports Q4 Revenue of $12.21B, Exceeds Consensus
select

News

seekingalpha
9.5
03-06seekingalpha
Baron Health Care Fund Reports Strong Q4 2025 Performance
  • Quarterly Growth: For the quarter ending December 31, 2025, the Baron Health Care Fund increased by 13.10%, significantly outperforming the Russell 3000 Health Care Index's 11.92% and the Russell 3000 Index's 2.40%, indicating strong performance in the healthcare sector.
  • Key Contributors: Companies such as Eli Lilly, Cidara Therapeutics, and Argenx SE were major contributors this quarter, reflecting ongoing momentum in GLP-1 therapies and innovation in biotechnology, which drove the fund's gains.
  • Portfolio Adjustments: The fund added seven new positions and exited ten during the quarter, bringing the total number of positions to 43, demonstrating its agile investment strategy in response to market changes.
  • Risk Management Actions: The fund reduced its positions in Stryker and Boston Scientific due to valuation concerns while also decreasing its stake in Arcellx to manage risks associated with increasing competition and regulatory challenges, showcasing its responsiveness to market dynamics.
Yahoo Finance
5.0
03-05Yahoo Finance
Thermo Fisher CEO Sells 10,000 Shares
  • Executive Sell-off: Marc N Casper, Chairman and CEO of Thermo Fisher, sold 10,000 shares on March 3, 2026, which may raise market concerns about the company's future performance, as executive sell-offs are often viewed as negative signals regarding company outlook.
  • Market Reaction: Such sell-off actions could lead to a decline in investor confidence in Thermo Fisher, potentially impacting its stock performance, especially in the current market environment where investors are particularly sensitive to executive signals.
  • Shareholding Structure Change: This transaction may alter Casper's ownership percentage, further influencing market perceptions of management stability, particularly as the company faces increasing competition.
  • Strategic Implications: While the sell-off may be interpreted as a negative signal, it could also be part of the executive's personal financial planning, prompting investors to focus on the company's future performance and strategic direction to assess its long-term investment value.
Fool
5.0
03-04Fool
Kemnay Advisory Services Increases Stake in MercadoLibre
  • Share Acquisition Details: Kemnay Advisory Services Inc. increased its position in MercadoLibre by 1,385 shares during Q4 2026, with an estimated trade value of $2.91 million, bringing total holdings to 5,623 shares and reflecting a $1.42 million increase from the previous quarter due to both trading and stock price effects.
  • Holding Proportion Analysis: Following this purchase, Kemnay's stake in MercadoLibre represents 1.71% of its 13F AUM, indicating a sustained bullish outlook on the company despite a 3.77% decline in share price over the past year.
  • Market Performance Overview: As of February 16, 2026, MercadoLibre shares were priced at $1,988.26, with a market capitalization of $100.80 billion, maintaining rapid revenue growth despite pressures from increased e-commerce competition and rising bad loans.
  • Investor Outlook: Kemnay has held MercadoLibre shares since Q2 2020, having previously sold off shares, but has now added shares in each of the last four quarters, suggesting they view the current stock price as an attractive buying opportunity, potentially leading to further purchases in the future.
Yahoo Finance
5.0
03-04Yahoo Finance
Kemnay Increases MercadoLibre Holdings by 1,385 Shares
  • Share Increase: Kemnay Advisory Services Inc. disclosed a purchase of 1,385 shares of MercadoLibre in Q4 2026, with an estimated trade value of $2.91 million, indicating confidence in the company's prospects.
  • Holding Status: As of February 2026, Kemnay's total holdings in MercadoLibre reached 5,623 shares, reflecting a $1.42 million increase from the previous quarter, showcasing a positive market sentiment.
  • Market Performance: Despite MercadoLibre's share price declining by 3.77% over the past year and trailing the S&P 500 by 15.56 percentage points, Kemnay's increased stake suggests they view the current price as attractive.
  • Investment Opportunity: Since acquiring shares in Q2 2020, Kemnay's recent purchases over the last four quarters may indicate confidence in the company's growth potential, particularly as economic conditions improve in Argentina and Venezuela.
CNBC
8.5
03-02CNBC
Novo Nordisk Invests €432 Million to Expand Wegovy Production
  • Investment Expansion: Novo Nordisk announced a €432 million ($506 million) investment in Ireland to expand production capacity for the Wegovy pill, aiming to meet future global demand, particularly outside the U.S. market.
  • Competitive Pressure: This investment follows Novo losing market share to Eli Lilly, with analysts noting that despite competitive pressures, this move demonstrates the company's commitment to the oral medication market, potentially helping to restore market confidence.
  • Supply Assurance: Novo has stated that it has resolved supply issues for Wegovy and has enough product to meet U.S. demand; however, challenges remain in meeting global demand, especially as it seeks to launch in other countries.
  • Future Outlook: The construction projects in Ireland are set to be completed gradually between 2027 and 2028, expected to include technological upgrades of existing facilities, further enhancing Novo's competitiveness in the obesity drug market, particularly in its strategic focus on oral medications.
moomoo
9.0
03-02moomoo
AIM Immunotech Inc. Enters Agreement with Thermo Fisher for Phase 3 Trial of Ampligen
  • Agreement Announcement: AIM Immunotech has signed an agreement with the Thermo Fisher Scientific for the Phase 3 trial of its drug Ampligen.

  • Trial Focus: The Phase 3 trial will focus on evaluating the efficacy and safety of Ampligen in treating specific medical conditions.

Wall Street analysts forecast TMO stock price to rise
19 Analyst Rating
Wall Street analysts forecast TMO stock price to rise
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
580.00
Averages
658.89
High
750.00
Current: 0.000
sliders
Low
580.00
Averages
658.89
High
750.00
Baird
Outperform
maintain
$645 -> $653
AI Analysis
2026-01-30
Reason
Baird
Price Target
$645 -> $653
AI Analysis
2026-01-30
maintain
Outperform
Reason
Baird raised the firm's price target on Thermo Fisher to $653 from $645 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results and it remains a top idea.
UBS
Neutral
maintain
$590 -> $615
2026-01-30
Reason
UBS
Price Target
$590 -> $615
2026-01-30
maintain
Neutral
Reason
UBS raised the firm's price target on Thermo Fisher to $615 from $590 and keeps a Neutral rating on the shares. Thermo Fisher's 2026 outlook is in-line with the firm's expectations, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TMO
Unlock Now

Valuation Metrics

The current forward P/E ratio for Thermo Fisher Scientific Inc (TMO.N) is 24.60, compared to its 5-year average forward P/E of 24.27. For a more detailed relative valuation and DCF analysis to assess Thermo Fisher Scientific Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
24.27
Current PE
24.60
Overvalued PE
27.08
Undervalued PE
21.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
20.91
Current EV/EBITDA
21.64
Overvalued EV/EBITDA
22.81
Undervalued EV/EBITDA
19.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.93
Current PS
4.83
Overvalued PS
5.56
Undervalued PS
4.30

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Humanoid robotics industry
Intellectia · 11 candidates
Themes: Robotics
Ticker
Name
Market Cap$
top bottom
TMO logo
TMO
Thermo Fisher Scientific Inc
186.47B
BA logo
BA
Boeing Co
181.50B
ISRG logo
ISRG
Intuitive Surgical Inc
174.07B
DE logo
DE
Deere & Co
159.30B
LMT logo
LMT
Lockheed Martin Corp
154.56B
NOC logo
NOC
Northrop Grumman Corp
107.31B
which stocks have only buy ratings?
Intellectia · 34 candidates
Market Cap: >= 20.00BAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.46T
MSFT logo
MSFT
Microsoft Corp
3.05T
AVGO logo
AVGO
Broadcom Inc
1.58T
AMD logo
AMD
Advanced Micro Devices Inc
325.19B
UNH logo
UNH
UnitedHealth Group Inc
262.11B
ABT logo
ABT
Abbott Laboratories
192.95B
suggest a few for swing trade
Intellectia · 7 candidates
Market Cap: >= 1000.00MRegion: USThemes: RoboticsRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Week Rise Prob: >= 0Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ROK logo
ROK
Rockwell Automation Inc
45.54B
ISRG logo
ISRG
Intuitive Surgical Inc
175.44B
TMO logo
TMO
Thermo Fisher Scientific Inc
193.72B
BA logo
BA
Boeing Co
183.29B
LMT logo
LMT
Lockheed Martin Corp
152.87B
NOC logo
NOC
Northrop Grumman Corp
103.28B
rsi below 35 in the s&p500
Intellectia · 22 candidates
Rsi Category: oversoldIs Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
TMO logo
TMO
Thermo Fisher Scientific Inc
192.95B
CRM logo
CRM
Salesforce Inc
175.96B
ACN logo
ACN
Accenture PLC
147.75B
BKNG logo
BKNG
Booking Holdings Inc
137.64B
PANW logo
PANW
Palo Alto Networks Inc
124.32B
INTU logo
INTU
Intuit Inc
108.41B
most bullish ticker 2026
Intellectia · 21 candidates
Market Cap: >= 5.00BMarket Cap Category: large, midAnalyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200One Month Rise Prob: >= 60
Ticker
Name
Market Cap$
top bottom
GLBE logo
GLBE
Global-E Online Ltd
5.91B
ALK logo
ALK
Alaska Air Group Inc
6.40B
CRDO logo
CRDO
Credo Technology Group Holding Ltd
23.10B
TMO logo
TMO
Thermo Fisher Scientific Inc
192.95B
IMVT logo
IMVT
Immunovant Inc
5.42B
COGT logo
COGT
Cogent Biosciences Inc
6.22B
best swing stock for today ?
Intellectia · 148 candidates
Market Cap: >= 1000.00MRsi Category: moderateRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Week Price Change Pct: $2.00 - $10.00
Ticker
Name
Market Cap$
top bottom
TMO logo
TMO
Thermo Fisher Scientific Inc
239.06B
KLAC logo
KLAC
KLA Corp
199.72B
AMGN logo
AMGN
Amgen Inc
185.02B
GEV logo
GEV
GE Vernova Inc
181.21B
IBKR logo
IBKR
Interactive Brokers Group Inc
128.56B
ARM logo
ARM
Arm Holdings PLC
120.87B
stocks that will pop today
Intellectia · 540 candidates
Relative Vol: >= 1.50Weekly Average Turnover: >= 1,000,000Week Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
MU logo
MU
Micron Technology Inc
437.95B
COST logo
COST
Costco Wholesale Corp
436.26B
AMD logo
AMD
Advanced Micro Devices Inc
406.68B
MS logo
MS
Morgan Stanley
290.20B
INTC logo
INTC
Intel Corp
258.77B
TMO logo
TMO
Thermo Fisher Scientific Inc
239.06B
Stocks at 52w highs and lows
Intellectia · 260 candidates
New High Low: 52w_High, 52w_Low
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
563.46B
HSBC logo
HSBC
HSBC Holdings PLC
285.69B
INTC logo
INTC
Intel Corp
258.77B
TMO logo
TMO
Thermo Fisher Scientific Inc
239.06B
BA logo
BA
Boeing Co
190.08B
GILD logo
GILD
Gilead Sciences Inc
160.18B
find me some good short term buys
Intellectia · 406 candidates
Relative Vol: >= 1.50Weekly Average Turnover: >= 1,000,000Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $2.00
Ticker
Name
Market Cap$
top bottom
MU logo
MU
Micron Technology Inc
437.95B
COST logo
COST
Costco Wholesale Corp
436.26B
AMD logo
AMD
Advanced Micro Devices Inc
406.68B
INTC logo
INTC
Intel Corp
258.77B
TMO logo
TMO
Thermo Fisher Scientific Inc
239.06B
KLAC logo
KLAC
KLA Corp
199.72B
what stock will do good this week
Intellectia · 112 candidates
Market Cap: >= 1000.00MRelative Vol: >= 1.50New High Low: 5_High
Ticker
Name
Market Cap$
top bottom
INTC logo
INTC
Intel Corp
258.77B
TMO logo
TMO
Thermo Fisher Scientific Inc
239.06B
AMGN logo
AMGN
Amgen Inc
185.02B
DHR logo
DHR
Danaher Corp
170.97B
Low logo
Low
Lowe's Companies Inc
155.45B
SBUX logo
SBUX
Starbucks Corp
109.65B

Whales Holding TMO

N
Needham Investment Management, LLC
Holding
TMO
+15.72%
3M Return
E
Evelyn Partners Investment Management LLP
Holding
TMO
+12.62%
3M Return
J
Journey Strategic Wealth LLC
Holding
TMO
+12.00%
3M Return
P
PGGM
Holding
TMO
+11.32%
3M Return
S
Snyder Capital Management, L.P.
Holding
TMO
+10.67%
3M Return
B
Border To Coast Pensions Partnership Limited
Holding
TMO
+10.36%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Thermo Fisher Scientific Inc (TMO) stock price today?

The current price of TMO is 501.86 USD — it has decreased -0.02

What is Thermo Fisher Scientific Inc (TMO)'s business?

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.

What is the price predicton of TMO Stock?

Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is658.89 USD with a low forecast of 580.00 USD and a high forecast of 750.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Thermo Fisher Scientific Inc (TMO)'s revenue for the last quarter?

Thermo Fisher Scientific Inc revenue for the last quarter amounts to 12.21B USD, increased 7.20

What is Thermo Fisher Scientific Inc (TMO)'s earnings per share (EPS) for the last quarter?

Thermo Fisher Scientific Inc. EPS for the last quarter amounts to 5.20 USD, increased 8.79

How many employees does Thermo Fisher Scientific Inc (TMO). have?

Thermo Fisher Scientific Inc (TMO) has 125000 emplpoyees as of March 09 2026.

What is Thermo Fisher Scientific Inc (TMO) market cap?

Today TMO has the market capitalization of 186.47B USD.